Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement